May 4, 2026
Novo Nordisk to launch Ozempic for type 2 diabetes in US
Novo Nordisk is set to launch Ozempic, its oral glucagon-like peptide-1 (GLP-1) receptor agonist pill for adults with type 2 diabetes, in the US.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







